Postoperative Pain Management Pipeline Analysis Report 2025

Postoperative pain management refers to the treatment of moderate-to-severe pain following surgical procedures, aiming to enhance recovery and patient comfort. The prevalence of such pain exhibits geographic variability, with rates ranging from 14% to 55% in Western countries. According to the postoperative pain management pipeline analysis by the publisher, the pipeline landscape is witnessing steady growth due to rising surgical volumes and increasing demand for safer, more effective therapeutics. The pipeline includes innovative non-opioid drugs, nerve block agents, and multimodal analgesic strategies, reflecting a strong focus on personalized and targeted therapies.

Report Coverage

The Postoperative Pain Management Pipeline Analysis Report by the publisher gives comprehensive insights into postoperative pain management therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for postoperative pain management. The postoperative pain management report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The postoperative pain management pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with postoperative pain management treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to postoperative pain management.

Postoperative Pain Management Pipeline Outlook

Postoperative pain management refers to the clinical practices used to control pain that arises after a surgical procedure. It occurs due to tissue damage, inflammation, or nerve irritation following surgery, often resulting in moderate to severe acute pain. Effective management is essential to promote healing, prevent complications, and improve patient comfort and recovery outcomes.

Postoperative pain is treated using a range of methods, including analgesics (opioid and non-opioid), regional anesthesia, and multimodal approaches to minimize pain while reducing side effects and opioid dependency. In January 2025, Vertex Pharmaceuticals Incorporated received FDA approval for Journavx (suzetrigine), a first-in-class oral non-opioid drug, marking a major advancement in the postoperative pain management pipeline.

Postoperative Pain Management Epidemiology

A 2024 study highlights a significant incidence of moderate to severe postoperative pain, with 41%-61% in developed countries and 60%-80% in developing nations. The American Pain Society reports a persistent prevalence exceeding 80%. In India alone, approximately 30 million surgical procedures are performed annually. These statistics underscore the urgent need for effective postoperative pain management, driving innovation and expansion in the drug development pipeline globally.

Postoperative Pain Management - Pipeline Therapeutic Assessment

This section of the report covers the analysis of postoperative pain management drug candidates based on several segmentations, including:

By Phase

• Late-Stage Products (Phase 3 and Phase 4)
• Mid-Stage Products (Phase 2)
• Early-Stage Products (Phase I)
• Preclinical and Discovery Stage Products

By Drug Class

• Small Molecules
• Biologics
• Natural Products
• Local Anesthetics
• Gene Therapies
• Others

By Route of Administration

• Oral
• Parenteral
• Others

Postoperative Pain Management Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to analysis, phase IV holds 50.58% of the postoperative pain management clinical trials, showcasing a strong presence of approved therapies with real-world effectiveness, driving confidence in market growth. Phase III accounts for 21.01%, indicating a healthy advancement of late-stage candidates. Phase II represents 15.95%, followed by phase I at 7.39% and early phase I at 5.06%, reflecting a promising and continuous innovation cycle in postoperative pain management.

Postoperative Pain Management Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the postoperative pain management pipeline analysis include small molecules, biologics, natural products, local anesthetics, gene therapies, and others. The postoperative pain management report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for postoperative pain management.

Opioid-based analgesics remain central in postoperative pain management for paediatric patients. For example, the POPCORN trial is evaluating the comparative side-effect profiles of intravenous morphine and oxycodone used in patient-controlled analgesia. This Phase 4 trial aims to assess differences in antiemetic use, opioid efficacy, and adverse effects, enhancing evidence-based opioid selection in clinical practice.

Postoperative Pain Management Clinical Trials - Key Players

The report for the postoperative pain management pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed postoperative pain management therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in postoperative pain management clinical trials:

• Avenue Therapeutics, Inc.
• Jiangsu HengRui Medicine Co., Ltd.
• Taiwan Liposome Company
• Pacira Pharmaceuticals, Inc.
• Arthritis Innovation Corporation
• Sinew Pharma Inc.
• Ocular Therapeutix, Inc.
• Heron Therapeutics
• Cali Pharmaceuticals LLC
• Apurano Pharmaceuticals GmbH

Postoperative Pain Management - Emerging Drugs Profile

This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for postoperative pain management. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of postoperative pain management drug candidates.

Drug: TLC590

TLC590, sponsored by Taiwan Liposome Company, is currently undergoing a Phase II/III trial to evaluate its safety, pharmacokinetics, and efficacy in postsurgical pain management after inguinal hernia repair. This liposomal formulation of ropivacaine aims to provide extended local pain relief. The study is assessing two doses of TLC590 through a double-blind, comparator- and placebo-controlled design.

Drug: Tramadol

IV Tramadol is being evaluated by Avenue Therapeutics, Inc. in a Phase III study comparing its efficacy and safety to placebo and morphine for managing post-operative pain after abdominoplasty. The study is examining IV tramadol’s dual mechanism - opioid receptor agonism and monoaminergic reuptake inhibition - as a novel approach to deliver effective analgesia with a potentially lower risk of abuse.

Key Questions Answered in the Postoperative Pain Management Pipeline Analysis Report

• Which companies/institutions are leading the postoperative pain management drug development?
• What is the efficacy and safety profile of postoperative pain management pipeline drugs?
• Which company is leading the postoperative pain management pipeline development activities?
• What is the current postoperative pain management commercial assessment?
• What are the opportunities and challenges present in the postoperative pain management pipeline landscape?
• What is the efficacy and safety profile of postoperative pain management pipeline drugs?
• Which company is conducting major trials for postoperative pain management drugs?
• Which companies/institutions are involved in postoperative pain management collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in postoperative pain management?

Reasons To Buy This Report

The Postoperative Pain Management Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for postoperative pain management. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into postoperative pain management collaborations, regulatory environments, and potential growth opportunities.

This product will be delivered within 3-5 business days.